Increased Expression Predicts Poor Prognosis and Disease Recurrence in Acute Myeloid Leukemia

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 May 24

PMID 31118680

Citations 20

Authors

Xi-Xi Li

Jing-Dong Zhou

Xiang-Mei Wen

Ting-Juan Zhang

De-Hong Wu

Zhao-Qun Deng

Zhi-Hui Zhang

Xin-Yue Lian

Pin-Fang He

Xin-Yu Yao

Jiang Lin

Jun Qian

Affiliations

Soon will be listed here.

Abstract

Altered expression of the family member has been linked to the progression and outcome of various malignancies. Recently, inhibitor S63845 was reported to kill -dependent cancer cells and has potential value in clinical application. Herein, we reported expression pattern in Chinese acute myeloid leukemia (AML) and its impact on prognosis and may provide theoretical basis for AML patients using inhibitor in clinics. Real-time quantitative PCR was carried out to detect the transcript of in AML patients. expression was significantly up-regulated in AML compared with controls (=0.042). We divided the patients into two groups (higher and lower expression of ) based on the median level. Among both non-acute promyelocytic leukemia (APL) and cytogenetically normal AML (CN-AML), patients with higher expression of correlated with lower complete remission (CR) rate (=0.031 and 0.004, respectively) and shorter overall survival (OS) time (=0.008 and 0.004, respectively) compared with those with lower expression of . Meanwhile, Cox regression analyses revealed that overexpression of acted as an independent risk factor for OS in non-APL patients and CN-AML patients (=0.011 and 0.045, respectively). In follow-up patients, expression level decreased after CR compared with newly diagnosis time (=0.020) and increased after relapse (=0.004). Our findings suggest that higher expression of predicts poor prognosis and can be used for disease monitoring.

Citing Articles

MEF2A is a transcription factor for circPVT1 and contributes to the malignancy of acute myeloid leukemia.

Wu K, Li Y, Nie B, Guo C, Ma X, Li L Int J Oncol. 2024; 65(5).

PMID: 39329212 PMC: 11436260. DOI: 10.3892/ijo.2024.5699.

BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.

Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F Nat Cancer. 2024; 5(10):1479-1493.

PMID: 39179926 PMC: 11502502. DOI: 10.1038/s43018-024-00814-0.

Evaluation of MCL-1 as a prognostic factor in canine mammary gland tumors.

Cho J, Chung H, Lee S, Kim W PLoS One. 2024; 19(7):e0306398.

PMID: 39012900 PMC: 11251587. DOI: 10.1371/journal.pone.0306398.

Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia.

Fisher-Wellman K, Kassai M, Hagen J, Neufer P, Kester M, Loughran Jr T Cancers (Basel). 2023; 15(6).

PMID: 36980769 PMC: 10046858. DOI: 10.3390/cancers15061883.

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.

Tecik M, Adan A Onco Targets Ther. 2022; 15:1449-1478.

PMID: 36474506 PMC: 9719701. DOI: 10.2147/OTT.S384293.

References

Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S . Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999; 93(9):3074-80. View

Grimwade D . The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001; 14(3):497-529. DOI: 10.1053/beha.2001.0152. View

Kuramoto K, Sakai A, Shigemasa K, Takimoto Y, Asaoku H, Tsujimoto T . High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Haematol. 2002; 116(1):158-61. DOI: 10.1046/j.1365-2141.2002.03253.x. View

Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U . Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002; 99(12):4326-35. DOI: 10.1182/blood.v99.12.4326. View

Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C . Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100(1):59-66. DOI: 10.1182/blood.v100.1.59. View

Tenen D . Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003; 3(2):89-101. DOI: 10.1038/nrc989. View

Bannerji R, Kitada S, Flinn I, Pearson M, Young D, Reed J . Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003; 21(8):1466-71. DOI: 10.1200/JCO.2003.06.012. View

Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan D . Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol. 2003; 75(1):22-33. DOI: 10.1002/ajh.10453. View

Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L . Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005; 352(3):254-66. DOI: 10.1056/NEJMoa041974. View

10.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

11.

Wuilleme-Toumi S, Robillard N, Gomez P, Moreau P, Le Gouill S, Avet-Loiseau H . Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia. 2005; 19(7):1248-52. DOI: 10.1038/sj.leu.2403784. View

12.

Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R . Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005; 106(8):2854-61. DOI: 10.1182/blood-2005-04-1733. View

13.

Verhaak R, Goudswaard C, van Putten W, Bijl M, Sanders M, Hugens W . Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005; 106(12):3747-54. DOI: 10.1182/blood-2005-05-2168. View

14.

Dzhagalov I, St John A, He Y . The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood. 2006; 109(4):1620-6. PMC: 1794052. DOI: 10.1182/blood-2006-03-013771. View

15.

Wang S, Fischer P . Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci. 2008; 29(6):302-13. DOI: 10.1016/j.tips.2008.03.003. View

16.

Pepper C, Lin T, Pratt G, Hewamana S, Brennan P, Hiller L . Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008; 112(9):3807-17. DOI: 10.1182/blood-2008-05-157131. View

17.

Schlenk R, Dohner K, Kneba M, Gotze K, Hartmann F, Del Valle F . Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2008; 94(1):54-60. PMC: 2625424. DOI: 10.3324/haematol.13378. View

18.

Mylin A, Rasmussen T, Lodahl M, Dahl I, Knudsen L . Upregulated MCL1 mRNA expression in multiple myeloma lacks association with survival. Br J Haematol. 2008; 144(6):961-3. DOI: 10.1111/j.1365-2141.2008.07521.x. View

19.

Kempkensteffen C, Hinz S, Johannsen M, Krause H, Magheli A, Christoph F . Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosis. Tumour Biol. 2009; 30(2):73-9. DOI: 10.1159/000215826. View

20.

Schlenk R, Dohner K . Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol. 2009; 16(2):98-104. DOI: 10.1097/MOH.0b013e3283257adb. View